Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

YM-337. Yamanouchi.

S Kamath1, G Y Lip

  • 1City Hospital, The University of Birmingham, University Department of Medicine, UK.

Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

State of play and future direction with NOACs: An expert consensus.

Vascular pharmacology·2018
Same author

Glycative and oxidative stress are associated with altered thrombus composition in diabetic patients with ST-elevation myocardial infarction.

International journal of cardiology·2017
Same author

Reply to Jolobe

The journal of the Royal College of Physicians of Edinburgh·2017
Same author

Clinical Stroke prevention in atrial fibrillation.

The journal of the Royal College of Physicians of Edinburgh·2017
Same author

Short runs of atrial arrhythmia and stroke risk: a European-wide online survey among stroke physicians and cardiologists.

The journal of the Royal College of Physicians of Edinburgh·2016
Same author

Decision support system for diabetic retinopathy using discrete wavelet transform.

Proceedings of the Institution of Mechanical Engineers. Part H, Journal of engineering in medicine·2013

YM-337, a humanized antibody targeting the glycoprotein (GP) IIb/IIIa receptor, is being developed for cardiovascular conditions. Clinical trials are evaluating its efficacy in patients with coronary artery disease and ischemic stroke.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Pharmacology

Background:

  • Coronary artery disease, myocardial infarction, arterial thrombosis, and ischemic stroke represent significant unmet medical needs.
  • Platelet aggregation via glycoprotein (GP) IIb/IIIa receptors is a key mechanism in thrombotic events.
  • Existing treatments for these conditions have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To evaluate the safety and efficacy of YM-337, a humanized antibody targeting the GP IIb/IIIa receptor.
  • To assess YM-337's potential in treating coronary artery disease, myocardial infarction, arterial thrombosis, and ischemic stroke.

Main Methods:

  • Development of YM-337 (C4G1), a humanized antibody derived from a murine antibody specific for the GP IIb/IIIa receptor.

Related Experiment Videos

  • Phase II clinical trials conducted in high-risk percutaneous transluminal coronary angioplasty (PTCA) patients.
  • Ongoing clinical investigations for the potential treatment of ischemic stroke.

    • Main Results:

    • YM-337 is under development through a collaboration between Yamanouchi and Protein Design Labs (PDL).
    • Phase II trials in Europe and the US for PTCA patients were ongoing as of May 2001.
    • Phase II trials for ischemic stroke were also underway in Europe and the US by May 2001.

    Conclusions:

    • YM-337 shows promise as a therapeutic agent for thrombotic cardiovascular events.
    • Further clinical evaluation is required to establish its definitive role in patient care.
    • The collaboration between Yamanouchi and PDL highlights a strategic approach to drug development.